OncoMatch/Clinical Trials/NCT04084730
Study of 3-Day Partial Breast Radiation Therapy in Women With Breast Cancer
Is NCT04084730 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies non-drug interventions for invasive ductal breast carcinoma.
The purpose of this study is to determine if the dose of radiation therapy that is effective in producing a treatment response, delivered over a shorter treatment period, is a safe approach that causes few or mild side effects in women with newly diagnosed breast cancer or DCIS who have had a lumpectomy procedure.
Check if I qualifyExtracted eligibility criteria
Cancer type
Breast Carcinoma
Biomarker criteria
Required: ESR1 positive
estrogen-receptor positive (ER+)
Excluded: BRCA1 mutation
if a patient is tested and is found to be a mutation carrier, she would be excluded from the study
Excluded: BRCA2 mutation
if a patient is tested and is found to be a mutation carrier, she would be excluded from the study
Disease stage
Required: Stage I
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Cannot have received: radiation therapy
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Norwalk Hospital · Norwalk, Connecticut
- Baptist Alliance Miami Cancer Institute · Miami, Florida
- Memorial Sloan Kettering Basking Ridge · Basking Ridge, New Jersey
- Memorial Sloan Kettering Monmouth · Middletown, New Jersey
- Memorial Sloan Kettering Bergen · Montvale, New Jersey
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT04084730 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior radiation therapy disqualifies patients from enrollment.
Does this trial require ESR1?
Yes, ESR1 positive is a required biomarker for enrollment.
Are patients with BRCA1 alterations eligible?
No. BRCA1 mutation is an exclusion criterion.
Are patients with BRCA2 alterations eligible?
No. BRCA2 mutation is an exclusion criterion.
What disease stage is eligible?
Stage I is required.
Is this trial open to male patients?
No. This trial enrolls female patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages